Stockscreener 앱 받기
3.337
1.78%
-0.033
전일 마감가:
$3.37
열려 있는:
$3.455
하루 거래량:
1,331
Relative Volume:
0.01
시가총액:
$7.28M
수익:
$368.00K
순이익/손실:
$-9.54M
주가수익비율:
-6.9695
EPS:
-0.4788
순현금흐름:
$-9.47M
1주 성능:
+2.16%
1개월 성능:
-71.47%
6개월 성능:
+327.21%
1년 성능:
+116.34%
1일 변동 폭
$3.455
$3.455
1주일 범위
$3.08
$3.84
52주 변동 폭
$0.35
$14.37
Lexaria Bioscience Corp Stock (LEXX) Company Profile
명칭
Lexaria Bioscience Corp
전화
250-765-6424
주소
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
3.455 | 7.10M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
521.23 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
193.91 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
958.75 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.30 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
Lexaria Bioscience (LEXX) pays $402K in warrant fees - Stock Titan
Lexaria Extends Cash Runway Through 2027 After $7.9 Million Capital Boost - TipRanks
Lexaria Bioscience Corp (NASDAQ: LEXX) Share Price, LEXX Stock News, LEXX Share Price & Updates - kalkine.com.au
Lexaria DHT3.0 boosts oral absorption for amycretin and retatrutide - scanx.trade
Lexaria Bioscience raises $7.9M, extends cash runway to 2027 By Investing.com - Investing.com Australia
Lexaria Bioscience secures $7.9M to extend cash runway through 2027 - scanx.trade
Lexaria Bioscience raises $7.9M, extends cash runway to 2027 - Investing.com
Lexaria Updates Financial Position - Weatherford Democrat
Lexaria Bioscience Corp. (NASDAQ:LEXX) Adds $7.9M Cash, Guides Runway Through 2027 - TradingView
A tax refund and financing give Lexaria cash through 2027 - Stock Titan
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - The Chronicle-Journal
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - Investing News Network
$5.9 million raised as Lexaria issues new rights to buy shares - Stock Titan
Lexaria Raises $5.9M in Warrant Exercise Transaction - Minichart
Lexaria Bioscience Raises $5.9 Million Via Warrant Exercise; Issues New Warrants, Engages Wainwright - TradingView
Primer: Lexaria Bioscience (LEXX US)Sep 2026 - Smartkarma
Lexaria Raises $5.9 Million Via Warrant Exercise and Issues New Warrants - TipRanks
Lexaria raises $5.9M by exercising warrants at reduced price to fund 2027 operations and R&D. - Pluang
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - investingnews.com
Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds - TradingView
A potential $5.9 million plus a $2.6 million rebate may fund Lexaria's 2027 research - Stock Titan
LEXX: Introducing DehydraTECH 3.0 - Yahoo Finance
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Lexaria to present at H.C. Wainwright Global Investment Conference in September 2026 - Pluang
A drug-delivery company holds 66 granted patents. Lexaria plans a New York presentation. - Stock Titan
Lexaria Bioscience Corp. (LEXX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs - The Globe and Mail
LEXX Looks 131.9% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience advances 12% on Australian tax rebate (LEXX:NASDAQ) - Seeking Alpha
Lexaria enters MTA with PegBio to test GLP-1 delivery tech - scanx.trade
LEXX Looks 129.0% Overvalued on GF Value™ - GuruFocus
Lexaria advances GLP-1 partnerships at BIO 2026 - scanx.trade
Lexaria Bioscience Receives Australian R&D Tax Incentive Credit - TipRanks
LEXX Looks 117.5% Overvalued on GF Value™ - GuruFocus
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com South Africa
Lexaria Bioscience receives AUD$3.67m Australian tax rebate - scanx.trade
Lexaria receives $2.6 million Australian R&D tax rebate - Investing.com
Lexaria nets $2.6M Australian tax rebate to fun... - Pluang
Lexaria Bioscience receives AUD 3.67M Australian R&D tax credit to fund clinical RD - TradingView
Lexaria Receives USD$2.6 Million Tax Rebate Payment - ncnewsonline.com
Lexaria DehydraTECH 3.0 Boosts GLP-1 Drug Absorption in 2026 Study - TipRanks
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 - Yahoo Finance
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com India
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com Nigeria
Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing - TipRanks
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed - Investing.com
Lexaria Bioscience regains Nasdaq bid-price compliance, listing continued - TradingView
Delisting risk eases as Lexaria (NASDAQ: LEXX) regains bid-price compliance - Stock Titan
Lexaria Bioscience enters MTA with PegBio - TipRanks
LEXX Looks 64.3% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know - Benzinga
Lexaria Bioscience Corp (LEXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.21%
1.05%
자본화:
|
볼륨(24시간):